Activity Expired

Evidence-Based Psychopharmacological Treatments for Youth in a Time of Regulatory Uncertainty
Laurence L. Greenhill, M.D., Chair

Sponsored by the AACAP Task Force on Intellectual Property, chaired by Robert Hendren, D.O.
Supported through an educational grant from Eli Lilly and Company.

PROGRAM GOALS AND OVERVIEW
The goal of the 2006 Psychopharmacology Update Online Program is to provide listeners with an update regarding the use of psychotropic medications to treat the psychiatric disorders of youth while being mindful of the increased attention on their safety and efficacy raised by the Food and Drug Administration. Practitioners will be exposed to expert opinions on their risk, benefit, and how to address parental concerns about using these medications to help their children with psychiatric disorders.

Learning Objectives
At the conclusion of this online CME activity, the participant should be able to:

1. Discuss the efficacy and safety of medication and non-medication treatments of pediatric depression.
2. Discuss the relationship between antipsychotics and weight gain, and the strategies to prevent and address antipsychotic related weight gain in children and adolescents.
3. Discuss optimal strategies for assessing, monitoring, and treating impulsive aggression, as well as side effects of its treatments.
4. Discuss the pharmacologic safety of new medications for the treatment of ADHD, and discuss methods of addressing concerns of families in dealing with adverse event warnings that appear in the drug package insert.
5. Describe the current treatment algorithm for treating bipolar mania and depression.
6. Identify the trends in medication use in children with pervasive developmental disorders and apply data from recent studies to initiation and ongoing management of pharmacological treatment in children with pervasive developmental disorders.
7. Recognize the key phenomenological distinctions among the pediatric anxiety disorders and pediatric major depressive disorder and identify available treatment options.
8. Describe new strategies and novel approaches for treatment refractory OCD and Tourette's Disorder in children and adolescents.
9. Identify the common endocrine complications of current psychopharmacological agents and how they relate to specific drugs

Target Audience
This educational activity is designed for child and adolescent psychiatrists, pediatricians, family practice physicians, and other healthcare professionals with a special interest in the psychopharmacological treatment of children and adolescents.

Release Date: June 15, 2006
Expiration Date: June 15, 2007

Continuing Medical Education Credit
This course is one in a continuing medical education series under the direction of the American Academy of Child and Adolescent Psychiatry's Institutes Subcommittee and the Task Force on Intellectual Property. The American Academy of Child and Adolescent Psychiatry is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Academy of Child and Adolescent Psychiatry designates this educational activity for a maximum of 12 hours of category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Method of Participation
The participant should, in order, read the objectives, view program content, complete the evaluation for each speaker, and if CME credit is needed, answer the multiple-choice online post-test. There is a fee for AACAP members / non-member who wish to take the CME post-test. A score of at least 70% is requi